NCT05933278View on ClinicalTrials.gov

Homologous Booster Study of COVID-19 Protein Subunit Recombinant Vaccine

PHASE2CompletedINTERVENTIONAL

Enrollment

150

Participants

Timeline

Start Date

July 25, 2023

Primary Completion Date

August 31, 2024

Study Completion Date

September 5, 2024

Conditions

COVID-19

Interventions

BIOLOGICAL

SARS-CoV-2 Subunit Recombinant Protein Vaccine

SARS-CoV-2 RBD subunit recombinant protein, manufactured by PT Bio Farma

Trial Locations (1)

Unknown

Faculty of Medicine Diponegoro University, Semarang

Sponsors

Lead Sponsor

All Listed Sponsors

lead

PT Bio Farma

INDUSTRY

NCT05933278 - Homologous Booster Study of COVID-19 Protein Subunit Recombinant Vaccine | Biotech Hunter | Biotech Hunter